Key Points {#FPar1}
==========

Proton pump inhibitors (PPIs) are prescribed for regular use to one in two residents of aged care services.There is a need to review whether indications for PPI use are still current when prescribing these medications for residents, and clearly document when PPIs are prescribed for gastroprotection in conjunction with specific gastric irritant medications.The opportunity exists to "step down" therapy and deprescribe PPIs in this setting.

Introduction {#Sec1}
============

Proton pump inhibitors (PPIs) are indicated for gastroesophageal reflux disease (GERD) and dyspepsia, Barrett's esophagus, and to prevent adverse gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs) \[[@CR1]--[@CR4]\]. An estimated 5.5% of all Australians use PPIs, with the highest prevalence of use among those aged over 80 years \[[@CR5]\]. Internationally, there is considerable variation in the prevalence of PPI use in residential aged care services (RACSs), ranging from 14 to 93% of residents \[[@CR6]--[@CR8]\].

The Australian Therapeutic Guidelines and American Gastroenterological Association recommend PPI use be limited to 4--8 weeks' duration for the symptomatic relief of uncomplicated GERD \[[@CR9], [@CR10]\]. If symptoms are not alleviated, the PPI dose may be increased or administered twice daily until symptoms are adequately controlled \[[@CR10], [@CR11]\]. However, periodic reassessment of the possibility to reduce the dose to the lowest effective dose once symptom relief is achieved is recommended. Long-term PPI use is not recommended for symptomatic relief of uncomplicated symptoms without further investigation, particularly if dose reduction or cessation is unsuccessful \[[@CR9]--[@CR11]\]. However, prophylactic PPI use may be suitable for older people at high risk of an ulcer who take concomitant gastric irritant medications such NSAIDs, including aspirin \[[@CR10]\]. Medications for symptom relief, such as PPIs, should also be routinely reviewed in people living with dementia because people living with dementia may under-report both disease-related symptoms and medication side effects \[[@CR12]\].

Proton pump inhibitors are considered generally safe and well tolerated medications with infrequent adverse events. However, vitamin B12 deficiencies, hypomagnesaemia, *Clostridium difficile* infection, community-acquired pneumonia, fractures, and renal injury have been associated with PPI use \[[@CR13]\]. Much of the evidence for these and other adverse events is limited or inconclusive. Nevertheless, frail older residents may be at increased risk of experiencing adverse events, particularly if high-dose PPIs are prescribed. Given the high prevalence of PPI use in RACSs, even rare adverse events may affect large numbers of residents \[[@CR14]\].

Existing literature suggest older people may be prescribed PPIs for long periods and without clear indications for use \[[@CR6]\]. Few studies have assessed duration of PPI use among residents of RACSs and whether residents have documented clinical indications for PPI use. A previous study utilizing data collected from 22 skilled nursing facilities in the USA found that one-quarter of residents prescribed a PPI did not have a valid indication for use and were not taking a concomitant NSAID or anticoagulant \[[@CR7]\].

There is increasing focus on regularly reviewing the need for PPI treatment in older people. Over the last decade, multiple national quality improvement initiatives directed at healthcare professionals and consumers have been implemented to improve PPI use in Australia \[[@CR14]\]. As part of the Choosing Wisely Australia initiative, the Gastroenterological Society of Australia and the Royal Australian College of General Practitioners both recommend that PPIs are not prescribed long term without attempting to reduce to the lowest possible dose or ceasing the PPI \[[@CR15]\]. The objective of this study was to characterize PPI use. We also determined factors associated with high-dose PPI use among older adults in RACSs.

Methods {#Sec2}
=======

Study Design, Setting, and Participants {#Sec3}
---------------------------------------

A secondary analysis of cross-sectional data collected from residents of six South Australian RACSs was undertaken. Five of the RACSs were located in metropolitan Adelaide and one was located in a regional center. RACSs provide assisted accommodation for people with care needs that can no longer be met at home \[[@CR16]\]. RACSs are synonymous with nursing homes and long-term care facilities in other countries. The study methods and characteristics of the cohort have been previously described \[[@CR17]\]. Briefly, adults aged 65 years or older were recruited between April and August 2014. Residents who were considered medically unstable (e.g., experiencing delirium) and residents with an estimated life expectancy of less than 3 months were excluded. Of the 664 residents in the 6 RACSs, 603 were invited to participate. Among the invited residents, 34 were excluded as the resident was medically unstable, hospitalized, or receiving palliative care, and a further 25 residents were excluded for other reasons. There were 106 residents who declined to participate and third-party consent could not be arranged for a further 54 residents. The final cohort comprised 383 residents. Participating residents were similar to all residents of the six RACSs in terms of age (mean age 87.5 years among participating residents vs. 87.3 years in all residents of the six RACSs), sex (77.5% female vs. 78.5% female) and diagnosed dementia (44.1% vs. 46.8%).

Data Collection {#Sec4}
---------------

Data collection was undertaken by three study nurses who had been trained in the administration of the tools. Data collected included activities of daily living (ADLs) measured with the six-item Katz ADL index \[[@CR18]\] and behavioral symptoms were assessed using the Neuropsychiatric Inventory Nursing Home version (NPI-NH) \[[@CR19]\]. Dementia severity was assessed using the 12-item Dementia Severity Rating Scale (DSRS) \[[@CR20]\] and frailty was screened using the seven-item FRAIL-NH scale \[[@CR21]\]. Residents' attitudes towards deprescribing were measured using the ten-item Patients' Attitude Towards Deprescribing (PATD) tool \[[@CR22]\]. The ADL, NPI-NH, and DSRS scales were completed in conjunction with a staff informant who had known the resident for at least 2 weeks. Diagnostic data were identified from the RACS electronic medical records. Charlson's Comorbidity Index (CCI) was calculated for each resident \[[@CR23]\]. The CCI consolidates individual coexisting medical diagnoses into a single, predictive variable.

Medication Use {#Sec5}
--------------

Medication administration charts for each resident were collected by study nurses on the day of study entry and reviewed by the research team. Each chart contained details of the medication name, dose form, strength, and administration frequency. Medications were defined as all prescription and non-prescription medications including topical preparations and nutritional and herbal supplements. The medication charts documented all medications prescribed on the day of study entry, and this was the primary exposure of interest for the present study; however, the history of medication prescribing prior to study entry available from each chart ranged from 1 day to more than 1 year prior to the date of data collection. This was because the medication charts were valid for use for up to several months once the chart was in use and the prescriber can choose to record the date a medication was first prescribed on the medication chart. Regular use was defined as the use of medications that were prescribed to be taken at regular intervals and written on the regular administration section of the medication chart. Regular use did not include medications listed in the pro re nata (PRN or "when required"), short-term use or nurse-initiated sections of the medication administration chart. Medication data were extracted from each chart and medications were classified using the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system \[[@CR24]\].

For the present cross-sectional study, details of all PPIs prescribed on the day of study entry for each resident were extracted for analysis. However, for all residents prescribed a PPI on the day of study entry, we also examined a copy of the medication chart collected on the day of study entry to identify if the duration of PPI use prior to study entry exceeded 8 weeks. PPIs were defined as pantoprazole (ATC code A02BC02), esomeprazole (A02BC05, A02BD06), lansoprazole (A02BC03), omeprazole (A02BC01), and rabeprazole (A02BC04). The criteria used to define low-, standard-, and high-dose PPI use are presented in Table [1](#Tab1){ref-type="table"}, and were consistent with dosing recommendations in Australia's national formulary \[[@CR11]\]. Long-term PPI use was defined as use greater than a period of 8 weeks from the date first prescribed (where documented on the current medication chart) or when duration of use shown on the current medication administration chart was greater than 8 weeks. Use of gastric irritant medications or medications associated with increased risk of gastrointestinal bleeding were defined as regular use of an NSAID (ATC code M01AB, M01AC, M01AE, M01AG, M01AH), aspirin (B01AC06, B01AC30, N02BA01), warfarin (B01AA03), apixaban (B01AF02), rivaroxaban (B01AF01), or dabigatran (B01AE07). Medication regimen complexity was calculated using the 65-item validated Medication Regimen Complexity Index (MRCI) \[[@CR25]\]. The MRCI incorporates a weighting corresponding to dosage form used, dosage frequency, and additional directions, with higher MRCI scores corresponding with more complex medication regimens.Table 1Definition of low-, standard-, and high-dose proton pump inhibitor (PPI) use that was applied in this studyTotal daily dose of the PPILow dose (mg)Standard dose (mg)High dose (mg)Pantoprazole≤ 2040\> 40Omeprazole≤ 1020\> 20EsomeprazoleN/A20\> 20Lansoprazole≤ 1530\> 30Rabeprazole≤ 1020\> 20

Main Outcome Measures {#Sec6}
---------------------

The main outcome measures included the proportion of residents receiving a PPI and the dose prescribed. We investigated factors associated with high-dose PPI use compared to standard/low-dose PPI use. We further investigated the duration of PPI use (greater than 8 weeks) and whether there was an indication consistent with PPI use (GERD, esophagitis, dyspepsia, Barrett's esophagus, peptic ulcer disease, Zollinger-Ellison syndrome, gastritis, or *Helicobacter pylori*) documented in the resident's current medical history. Concomitant, regular use of gastric irritant medications or medications associated with increased bleeding risk on the day of study entry was also determined from medication administration charts.

Statistical Analyses {#Sec7}
--------------------

Descriptive statistics were used to summarize resident characteristics, PPI use, and treatment. Wilcoxon rank sum tests were used to compare continuous variables with skewed distributions, *t* tests were used to compare continuous variables that were normally distributed, and Chi square tests were used to compare categorical variables. Logistic regression models were used to determine unadjusted and age- and sex-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between demographic, clinical, and medication-related factors and high-dose PPI use (vs. use of low/standard PPI dose). Multiple imputation with five iterations was used to impute missing values for ADL score (1.3% missing) and FRAIL-NH score (1.0% missing) for the age- and sex-adjusted regression models. *P* values of \< 0.05 were considered statistically significant. All data were analyzed using SAS software v 9.4 (SAS Institute, Cary, NC, USA).

Compliance with Ethical Standards {#Sec8}
---------------------------------

This study was approved by the Monash University Human Research Ethics Committee and the Royal Australian College of General Practitioners National Research and Evaluation Ethics Committee. The study was conducted in accordance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained for all residents participating in this study. Written informed consent was obtained from the resident's guardian, next of kin, or significant other when a resident was unable to provide informed consent.

Results {#Sec9}
=======

The 383 residents who participated in this study had an average age of 88 years, 76% were female, and 44% had a documented diagnosis of dementia (Table [2](#Tab2){ref-type="table"}). The characteristics of residents who did and did not receive a PPI are compared in Table [2](#Tab2){ref-type="table"}.Table 2Clinical and demographic characteristics of residents, stratified by proton pump inhibitor (PPI) useAll residents (*n* = 383)PPI useNo (*n* = 187)Yes (*n* = 196)*P* valueAge, years, mean (SD)88 (6)87 (6)88 (6)0.42Female (*n*, %)297 (76)141 (76)158 (79)0.46High care needs (*n*, %)135 (35)72 (39)63 (32)0.19Charlson Comorbidity Index score, median (IQR)2 (1--3)2 (1--3)2 (1--3)0.10Dementia (*n*, %)169 (44)106 (57)63 (32)\< 0.001Dementia severity rating scale score, mean (SD) (*n* = 380)19 (17)22 (18)(*n* = 186)16 (16)(*n* = 194)\< 0.001FRAIL-NH score, mean (SD) (*n* = 379)4.70 (4)5 (4)(*n* = 185)4 (4)(*n* = 194)0.08Activities of daily living score, mean (SD) (*n* = 378)3.4 (2)3.2 (2.3)(*n* = 184)3.6 (2.3)(*n* = 194)0.15Number of regular charted medications, median (IQR)10 (7--13)8 (6--11)11 (9--14)\< 0.001Medication regimen complexity index score, median (IQR)44 (33--56)40 (27--49)42 (37--61)\< 0.001Neuropsychiatric Index score^a^, median (IQR)2 (0--10)3 (0--12)2 (0--8)0.03*IQR* interquartile range, *SD* standard deviation^a^*n* = 37 residents were missing data on at least one NPI item (18 non-users and 19 PPI users)

There were 196 (51%) residents who were prescribed a PPI. Of these, seven residents (3.6% of residents receiving a PPI) were prescribed a low-dose PPI, 143 (73.0%) received a standard dose and 45 (23%) residents received a high-dose PPI (Table [3](#Tab3){ref-type="table"}). Pantoprazole and esomeprazole together represented approximately 80% of PPI use. Twice-daily administration was identified for 21 residents (10% of PPI users). The PPI was prescribed for regular use for all 196 residents, with no residents prescribed PRN PPIs.Table 3Descriptive information for residents who received a proton pump inhibitor (PPI)Any PPI, *n* (%)PPI dose^a^Standard or low dose, *n* (%)High dose, *n* (%)Prescribed PPI196 (100)150 (77)45 (23)PPI type Pantoprazole97 (48)81 (54)14 (31) Omeprazole19 (9)14 (9)4 (9) Esomeprazole64 (32)35 (23)28 (62) Lansoprazole6 (3)6 (4)0 (0) Rabeprazole17 (8)14 (9)1 (6)Frequency of PPI use Once daily175 (89)147 (98)28 (62) Twice daily21 (10)3 (2)17 (38) More than twice daily0 (0)0 (0)0 (0) Pro re nata (when required)0 (0)0 (0)0 (0)Documented indication for PPI use145 (74)113 (75)32 (71)Indication for PPI use GERD121 (62)92 (61)29 (66) Esophagitis13 (7)12 (8)1 (2) Dyspepsia3 (2)3 (2)0 (0) Barrett's esophagus5 (3)5 (3)0 (0) Peptic ulcer disease12 (6)9 (6)3 (7) Gastritis9 (5)8 (5)1 (2) *Helicobacter pylori*1 (1)0 (0)1 (2) Other5 (3)4 (3)1 (2)No. of residents with GERD or dyspepsia using PPI for \> 8 weeks based on current medication chart93/123 (76)68/94 (72)25/29 (86)Concomitant medication associated with increased bleeding risk or gastric irritation NSAID or aspirin82 (42)62 (41)20 (44)  NSAID14 (7)11 (7)3 (7)  Aspirin73 (37)53 (35)20 (44) Oral anticoagulant26 (13)21 (14)5 (11) At least one of the above medications108 (55)82 (55)25 (56)Neither a documented indication nor medication associated with increased bleeding risk or gastric irritation23 (12)17 (11)6 (13)*GERD* gastroesophageal reflux disease, *NSAID* non-steroidal anti-inflammatory drug^a^Dose not documented for one resident

Overall, 145 (74%) residents receiving a PPI had at least one documented clinical indication for PPI use, of which the most frequent was GERD (Table [3](#Tab3){ref-type="table"}). Approximately half of all residents (55%) prescribed a PPI were also prescribed one or more medications associated with gastric irritation or increased risk of gastrointestinal bleeding. Neither an indication nor a medication associated with increased bleeding risk or gastric irritation was identified for 23 (12%) residents prescribed a PPI.

Among the 196 residents who received a PPI, the duration of PPI prescribing could be established for 147 (75%) residents based on the current medication chart. A PPI was taken for longer than 8 weeks in almost all residents (*n* = 141, 96%) where the current medication chart included at least 8 weeks of PPI prescribing data. Of the 124 residents with documented GERD or dyspepsia who were prescribed a PPI, 123 residents had sufficient information recorded on the medication chart to assess whether the PPI had been prescribed for more than 8 weeks, and three-quarters (*n* = 93, 76%) had received a PPI for more than 8 weeks (Table [3](#Tab3){ref-type="table"}).

Overall, 142 (72%) residents receiving a PPI were able to self-report their willingness for medications to be deprescribed. Of these, few residents (8%) were comfortable with the number of medications taken and most residents (83%) indicated a willingness to stop one or more regular medications if their doctor said it was possible (Table [4](#Tab4){ref-type="table"}).Table 4Percentage agreement with the 10-item Patients' Attitude Towards Deprescribing (PATD) questionnaire among residents receiving a proton pump inhibitor (PPI) who could complete the PATDResponse to PATD questionTotal (*n* = 142)PPI dose^a^Standard or low dose (*n* = 105)High dose (*n* = 36)I feel that I am taking a large number of medications69 (49)50 (48)18 (50)I am comfortable with the number of medications that I am taking11 (8)8 (8)3 (8)I believe that all my medications are necessary107 (75)78 (74)28 (78)If my doctor said it was possible, I would be willing to stop one or more of my regular medications118 (83)87 (83)30 (83)I would like to reduce the number of medications that I am taking61 (43)46 (44)15 (42)I feel that I may be taking one or more medications that I no longer need25 (18)18 (17)7 (19)I would accept taking more medications for my health conditions85 (60)61 (58)23 (64)I have a good understanding of the reasons I was prescribed each of my medications96 (68)68 (65)27 (75)Having to pay for fewer medications would play a role in my willingness to stop one or more of my medications22 (15)15 (14)7 (19)I believe one or more of my medications are giving me side effects22 (15)14 (13)8 (22)Percentage agreement combined those residents who agreed and strongly agreed*PPI* proton pump inhibitor^a^Dose not documented for one resident

Characteristics associated with high-dose PPI use compared to low or standard doses are shown in Table [5](#Tab5){ref-type="table"}. A greater number of medications prescribed for regular administration and increasingly complex medication regimens were significantly associated with the use of a high-dose PPI. High-dose PPI use was not found to be associated with dementia, frailty, independence in ADLs, or increased NPI-NH scores in the age- and sex-adjusted analyses.Table 5Logistic regression to identify factors associated with use of a high--dose proton pump inhibitor (PPI) compared to a standard/low--dose PPIUnadjusted odds ratio (95% CI)Age and sex adjusted odds ratio (95% CI)Age0.96 (0.90--1.01)0.96 (0.91--1.01)Female0.66 (0.30--1.43)0.73 (0.33--1.61)High care needs0.52 (0.24--1.14)0.56 (0.25--1.23)Dementia0.71 (0.34--1.48)0.70 (0.33--1.48)FRAIL-NH score^a^1.00 (0.92--1.09)1.01 (0.93--1.10)Activities of daily living score^a,b^1.03 (0.89--1.19)1.01 (0.87--1.18)Number of regularly prescribed medications1.11 (1.01--1.21)1.11 (1.01--1.21)Medication regimen complexity index score1.02 (1.01--1.04)1.02 (1.01--1.04)Neuropsychiatric index score^c^0.98 (0.95--1.02)0.98 (0.95--1.02)Documented indication for PPI use0.81 (0.38--1.70)0.80 (0.38--1.69)Gastroesophageal reflux disease (compared to absent or not documented)1.14 (0.57--2.29)1.12 (0.55--2.25)Other indications for PPI use (compared to absent or not documented)0.44 (0.13--1.55)0.46 (0.13--1.62)Concurrent medication use Oral non--steroidal anti--inflammatory drug or aspirin1.13 (0.58--2.22)1.05 (0.53--2.08) Oral anticoagulant0.77 (0.27--2.17)0.64 (0.22--1.86)*CI* confidence interval^a^Analyses utilized imputed data^b^Increased scores reflect greater independence with activities of daily living^c^Total Neuropsychiatric Inventory score could be determined for *n* = 171 residents

Discussion {#Sec10}
==========

This study characterizing PPI use in 6 Australian RACSs showed that half of all residents receive a PPI on a regular basis. Our study findings are consistent with other research in RACSs suggesting that PPI use is highly prevalent \[[@CR6]--[@CR8]\]. Furthermore, our finding that residents taking high-dose PPIs had high levels of polypharmacy and medication regimen complexity compared to low/standard-dose users is consistent with previous RACS research that found PPIs were taken by 72% of residents receiving nine or more regular medications compared to 36% receiving fewer than nine medications \[[@CR26]\]. Previous research has predominantly investigated prevalence of PPI use in RACSs using defined daily doses or without assessing dose. We found that three in four residents who took a PPI received a standard dose. Less than 4% of residents who took a PPI received a low-dose PPI. It is also important for prescribers to document the indication and intended duration when prescribing a PPI for a resident of an aged care service. Nearly nine in ten residents taking a PPI had a documented indication consistent with PPI use. However, three-quarters of residents with GERD or dyspepsia charted a PPI had taken the PPI for more than 8 weeks. These findings are similar to a recent Canadian study involving 147 residents who were prescribed a PPI, of whom 62% of residents with GERD had received the PPI for more than 8 weeks, and one in five residents taking a PPI had no documented indication for PPI use \[[@CR27]\].

Our findings suggest that stepping-down therapy to lower doses may be appropriate for up to one-quarter of residents who received a high-dose PPI. The finding that many residents with GERD or dyspepsia had received a PPI for more than 8 weeks also suggests there are opportunities for stepping-down therapy. Further, residents who took PPIs long term without an apparent indication and residents with documented dyspepsia or GERD who had received a PPI for more than 8 weeks may be suitable candidates for deprescribing \[[@CR6], [@CR28]\]. Deprescribing refers to "reducing medications after consideration of therapeutic goals, benefits and risks, and medical ethics" \[[@CR29]\]. Deprescribing PPIs can be challenging, as abrupt cessation may result in rebound symptoms, possibly due to acid hypersecretion \[[@CR30], [@CR31]\]. Deprescribing for residents living with dementia can also be complicated by medical practitioner and systems-related barriers such as lack of time or resources, or fear of negative consequences \[[@CR32]\]. Difficulties with decision-making, comprehension, and communication among residents with dementia may also limit deprescribing \[[@CR32]\]. However, in our study, the residents' willingness to consider deprescribing indicates that it may be feasible in this population to attempt PPI dose de-escalation or deprescribing. Residents taking PPIs in the present study also had high levels of polypharmacy and medication regimen complexity, and therefore could potentially benefit from deprescribing. Translational research could test and implement targeted strategies for stepping-down therapy among residents receiving high-dose PPIs and for deprescribing PPIs prescribed for treating GERD or dyspepsia for more than 8 weeks. This process could be informed by recommendations from both the Canadian guidelines for deprescribing PPIs and a recent systematic review \[[@CR28], [@CR33]\], and known resident, caregiver, and prescriber facilitators and barriers to deprescribing, particularly in people with dementia \[[@CR34], [@CR35]\], as well as previous deprescribing controlled trials in RACSs. Interdisciplinary approaches may be more likely to facilitate the optimization of PPI use among older people. For example, previous Australian research has indicated that repeated multifaceted quality improvement interventions targeting clinicians and older veterans taking a PPI to encourage PPI dose reductions have achieved sustained improvements in PPI use \[[@CR14]\].

Study strengths include investigation of PPI use in RACSs, including medication selection and dose, within a modest sample size of residents. Our sample included residents from metropolitan and rural areas and was representative of all residents in the six RACSs from which the participating residents were recruited. The six RACSs were maintained by the same aged care provider organization, and therefore findings may not be generalizable to all Australians receiving residential aged care services. In Australia, 59% of residents of aged care services are aged 85 years and over, 68% of residents are female, and 52% of residents are living with dementia \[[@CR36], [@CR37]\].

To our knowledge, this is one of the first studies to investigate guideline-appropriate PPI use in RACSs that has considered PPI dose and duration. Because only three-quarters of residents receiving a PPI had medication charts with more than 8 weeks of prescribing data available, our study may have underestimated the proportion of residents using PPIs for longer than 8 weeks. The cross-sectional nature of this study also meant we could not assess causation or changes in PPI use over an extended period. We were unable to reliably assess previous attempts at dose changes or withdrawals as while we could extract the date the PPI was prescribed from some medication charts, we lacked continuous information on PPI dose and administration for all residents prior to study entry. We were also unable to determine the circumstances under which the PPI was originally prescribed and any adverse events experienced by study participants. Although older age is a risk factor for gastrointestinal bleeding associated with NSAIDs or anticoagulants \[[@CR10]\], we were unable to determine whether PPI prophylaxis was warranted for all residents who received a gastric irritant medication or a medication associated with increased risk of gastrointestinal bleeding. There was also a small number of residents taking a PPI with a diagnosis of gastritis recorded in the medical history, and this was defined as a potential indication for PPI use in this study. We recognize that gastritis may not be an approved indication for PPI use in all settings, and therefore the proportion of residents who had at least one documented clinical indication for PPI treatment may be slightly overestimated. Finally, we explored associations using age- and sex-adjusted models, but our modest sample size prevented exploration using multivariable models, and therefore residual confounding may still exist.

Conclusions {#Sec11}
===========

Despite PPI use being highly prevalent, many residents taking a PPI had documented clinical indications for treatment. This is contrary to the popular belief that PPIs should be targeted for deprescribing due to lack of clear clinical indications in RACSs and could be further explored in future studies. However, there remains an opportunity to review the continuing need for PPI use among residents with GERD who are treated for more than 8 weeks, and identify if residents using higher PPI doses are suitable for "step-down" approaches to treatment. There is also a need for clinicians to specify when PPIs are prescribed for gastroprotection and clearly document whether indications for PPI use are still current.
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